12 months from date of receipt / reconstitution, 2 to 8 °C as supplied
Pembrolizumab is a humanized monoclonal IgG4 kappa antibody directed against human cell surface PD-1 (programmed death receptor-1) on lymphocytes. The PD-1 receptor provides an important “immune checkpoint,” which helps prevent the immune system from attacking itself.
Pembrolizumab (anti-PD-1), dilutions start from 1 μg/ml) can bind to Immobilized recombinant Human PD-1 his tag (UA010004 form UA.BIO) at 0.5 μg/ml (50 μl/well) as coating antigen.
EC50=13.74 ng/ml
您现在的位置：